Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Predictors of extensive lymphatic dissemination and recurrences in node-positive endometrial cancer.

Zanfagnin V, Huang Y, Mc Gree ME, Weaver AL, Casarin J, Multinu F, Cappuccio S, Ferrero A, Mariani A, Glaser GE.

Gynecol Oncol. 2019 Jul 16. pii: S0090-8258(19)31391-5. doi: 10.1016/j.ygyno.2019.07.006. [Epub ahead of print]

PMID:
31324453
2.

Workplace Harassment and Discrimination in Gynecology: Reflections on the Report of the American Association of Gynecologic Laparoscopists Member Survey.

Gostout B, Glaser G, Torbenson V.

J Minim Invasive Gynecol. 2019 Jul - Aug;26(5):785-786. doi: 10.1016/j.jmig.2019.05.010. Epub 2019 May 22. No abstract available.

PMID:
31128283
3.

Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer.

Multinu F, Casarin J, Cappuccio S, Keeney GL, Glaser GE, Cliby WA, Weaver AL, McGree ME, Angioni S, Faa G, Leitao MM Jr, Abu-Rustum NR, Mariani A.

Gynecol Oncol. 2019 Jul;154(1):60-64. doi: 10.1016/j.ygyno.2019.05.008. Epub 2019 May 22.

4.

Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update.

Nelson G, Bakkum-Gamez J, Kalogera E, Glaser G, Altman A, Meyer LA, Taylor JS, Iniesta M, Lasala J, Mena G, Scott M, Gillis C, Elias K, Wijk L, Huang J, Nygren J, Ljungqvist O, Ramirez PT, Dowdy SC.

Int J Gynecol Cancer. 2019 Mar 15. pii: ijgc-2019-000356. doi: 10.1136/ijgc-2019-000356. [Epub ahead of print]

PMID:
30877144
5.

Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists.

Casarin J, Multinu F, Abu-Rustum N, Cibula D, Cliby WA, Ghezzi F, Leitao M, Konishi I, Nam JH, Querleu D, Soliman PT, Yost KJ, Weaver AL, Mariani A, Glaser GE.

Int J Gynecol Cancer. 2019 Jan;29(1):60-67. doi: 10.1136/ijgc-2018-000020.

PMID:
30640685
6.

Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies.

Tortorella L, Casarin J, Mara KC, Weaver AL, Multinu F, Glaser GE, Cliby WA, Scambia G, Mariani A, Kumar A.

Gynecol Oncol. 2019 Jan;152(1):151-156. doi: 10.1016/j.ygyno.2018.10.036. Epub 2018 Nov 8.

PMID:
30414740
7.

Enhanced Recovery after Minimally Invasive Gynecologic Procedures with Bowel Surgery: A Systematic Review.

Kalogera E, Glaser GE, Kumar A, Dowdy SC, Langstraat CL.

J Minim Invasive Gynecol. 2019 Feb;26(2):288-298. doi: 10.1016/j.jmig.2018.10.016. Epub 2018 Oct 24. Review.

PMID:
30366117
8.

Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23. No abstract available.

9.

Enhanced recovery after surgery in gynecologic oncology.

Glaser G, Dowdy SC, Peedicayil A.

Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:143-146. doi: 10.1002/ijgo.12622.

PMID:
30306585
10.

Frozen Section to Detect Empty Nodes and Improve the Accuracy of the Sentinel Lymph Node Biopsy in Endometrial Cancer.

Casarin J, Glaser G.

Ann Surg Oncol. 2018 Nov;25(12):3699-3700. doi: 10.1245/s10434-018-6770-5. Epub 2018 Sep 17. No abstract available.

PMID:
30225836
11.

Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.

Schlappe BA, Weaver AL, Ducie JA, Eriksson AGZ, Dowdy SC, Cliby WA, Glaser GE, Soslow RA, Alektiar KM, Makker V, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2018 Nov;151(2):235-242. doi: 10.1016/j.ygyno.2018.08.022. Epub 2018 Aug 31.

PMID:
30177461
12.

Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs.

Kumar A, Wallace SA, Cliby WA, Glaser GE, Mariani A, Leitao MM, Frumovitz M, Langstraat CL.

J Minim Invasive Gynecol. 2019 May - Jun;26(4):727-732. doi: 10.1016/j.jmig.2018.08.006. Epub 2018 Aug 20.

PMID:
30138740
13.

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Erratum in: Gynecol Oncol. 2018 Oct 22;:.

PMID:
30135020
14.

Frozen Section for Detection of Lymph Nodes After Cervical Injection with Indocyanine Green (ICG) for Sentinel Lymph Node Technique in Endometrial Cancer Staging.

Casarin J, Multinu F, Pasupathy K, Weaver A, McGree M, Tortorella L, Torres D, Kumar A, Langstraat C, Huang Y, Ghezzi F, Mariani A, Glaser G.

Ann Surg Oncol. 2018 Nov;25(12):3692-3698. doi: 10.1245/s10434-018-6698-9. Epub 2018 Aug 16.

PMID:
30116949
15.

Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer.

Matsuo K, Machida H, Mariani A, Mandelbaum RS, Glaser GE, Gostout BS, Roman LD, Wright JD.

J Gynecol Oncol. 2018 Sep;29(5):e69. doi: 10.3802/jgo.2018.29.e69. Epub 2018 May 4.

16.

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA.

Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15.

PMID:
29550184
17.

Adjuvant therapy for women with high-risk endometrial carcinoma.

Dowdy SC, Glaser GE.

Lancet Oncol. 2018 Mar;19(3):268-269. doi: 10.1016/S1470-2045(18)30091-3. Epub 2018 Feb 12. No abstract available.

18.

Adoption of Minimally Invasive Surgery and Decrease in Surgical Morbidity for Endometrial Cancer Treatment in the United States.

Casarin J, Multinu F, Ubl DS, Dowdy SC, Cliby WA, Glaser GE, Butler KA, Ghezzi F, Habermann EB, Mariani A.

Obstet Gynecol. 2018 Feb;131(2):304-311. doi: 10.1097/AOG.0000000000002428.

PMID:
29324598
19.

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.

Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.

Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.

20.

Clinical Utility of Preoperative Computed Tomography in Patients With Endometrial Cancer.

Bogani G, Gostout BS, Dowdy SC, Multinu F, Casarin J, Cliby WA, Frigerio L, Kim B, Weaver AL, Glaser GE, Mariani A.

Int J Gynecol Cancer. 2017 Oct;27(8):1685-1693. doi: 10.1097/IGC.0000000000001076.

PMID:
28704325
21.

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P.

PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867. eCollection 2015.

22.

Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer.

Janco JM, Glaser G, Kim B, McGree ME, Weaver AL, Cliby WA, Dowdy SC, Bakkum-Gamez JN.

Gynecol Oncol. 2015 Jul;138(1):70-7. doi: 10.1016/j.ygyno.2015.04.013. Epub 2015 Apr 22.

PMID:
25913130
23.

Therapeutic applications of hypnosis.

Glaser GP.

Am J Clin Hypn. 2014 Apr;56(4):320-1. No abstract available.

PMID:
24938073
24.

HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase.

Kaspy I, Rotem E, Weiss N, Ronin I, Balaban NQ, Glaser G.

Nat Commun. 2013;4:3001. doi: 10.1038/ncomms4001.

PMID:
24343429
25.

Design, synthesis and structure-activity relationship of novel Relacin analogs as inhibitors of Rel proteins.

Wexselblatt E, Kaspy I, Glaser G, Katzhendler J, Yavin E.

Eur J Med Chem. 2013;70:497-504. doi: 10.1016/j.ejmech.2013.10.036. Epub 2013 Oct 22.

PMID:
24189495
26.

The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.

Glaser G, Torres M, Kim B, Aletti G, Weaver A, Mariani A, Hartmann L, Cliby W.

Gynecol Oncol. 2013 Aug;130(2):280-3. doi: 10.1016/j.ygyno.2013.05.007. Epub 2013 May 11.

27.

Policy: Sustainable development goals for people and planet.

Griggs D, Stafford-Smith M, Gaffney O, Rockström J, Ohman MC, Shyamsundar P, Steffen W, Glaser G, Kanie N, Noble I.

Nature. 2013 Mar 21;495(7441):305-7. doi: 10.1038/495305a. No abstract available.

PMID:
23518546
28.

Policy: Base sustainable development goals on science.

Glaser G.

Nature. 2012 Nov 1;491(7422):35. doi: 10.1038/491035a. No abstract available.

PMID:
23128211
29.

Relacin, a novel antibacterial agent targeting the Stringent Response.

Wexselblatt E, Oppenheimer-Shaanan Y, Kaspy I, London N, Schueler-Furman O, Yavin E, Glaser G, Katzhendler J, Ben-Yehuda S.

PLoS Pathog. 2012 Sep;8(9):e1002925. doi: 10.1371/journal.ppat.1002925. Epub 2012 Sep 20.

30.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P.

Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1.

31.

ppGpp analogues inhibit synthetase activity of Rel proteins from Gram-negative and Gram-positive bacteria.

Wexselblatt E, Katzhendler J, Saleem-Batcha R, Hansen G, Hilgenfeld R, Glaser G, Vidavski RR.

Bioorg Med Chem. 2010 Jun 15;18(12):4485-97. doi: 10.1016/j.bmc.2010.04.064. Epub 2010 Apr 28.

PMID:
20483622
32.

Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed?

Khoury-Collado F, Glaser GE, Zivanovic O, Sonoda Y, Levine DA, Chi DS, Gemignani ML, Barakat RR, Abu-Rustum NR.

Gynecol Oncol. 2009 Dec;115(3):453-5. doi: 10.1016/j.ygyno.2009.08.026. Epub 2009 Sep 19.

PMID:
19767064
33.

Energetics of MazG unfolding in correlation with its structural features.

Drobnak I, Korencic A, Loris R, Marianovsky I, Glaser G, Jamnik A, Vesnaver G, Lah J.

J Mol Biol. 2009 Sep 11;392(1):63-74. doi: 10.1016/j.jmb.2009.05.086. Epub 2009 Jun 10.

PMID:
19523960
34.

Reflections of a previous editor of Epilepsia.

Glaser GH.

Epilepsia. 2009 Mar;50(3):349-50. doi: 10.1111/j.1528-1167.2009.02028.x. No abstract available.

35.

Da Vinci-assisted abdominal cerclage.

Barmat L, Glaser G, Davis G, Craparo F.

Fertil Steril. 2007 Nov;88(5):1437.e1-3.

PMID:
17991516
36.

Comparative insights into questions of lepidopteran wing pattern homology.

Monteiro A, Glaser G, Stockslager S, Glansdorp N, Ramos D.

BMC Dev Biol. 2006 Nov 7;6:52.

37.

Expression of connexin47 in oligodendrocytes is regulated by the Sox10 transcription factor.

Schlierf B, Werner T, Glaser G, Wegner M.

J Mol Biol. 2006 Aug 4;361(1):11-21. Epub 2006 Jun 15.

PMID:
16822525
38.

MazG -- a regulator of programmed cell death in Escherichia coli.

Gross M, Marianovsky I, Glaser G.

Mol Microbiol. 2006 Jan;59(2):590-601.

39.

Energetics of structural transitions of the addiction antitoxin MazE: is a programmed bacterial cell death dependent on the intrinsically flexible nature of the antitoxins?

Lah J, Simic M, Vesnaver G, Marianovsky I, Glaser G, Engelberg-Kulka H, Loris R.

J Biol Chem. 2005 Apr 29;280(17):17397-407. Epub 2005 Feb 27.

40.

Buffering of stable RNA promoter activity against DNA relaxation requires a far upstream sequence.

Rochman M, Blot N, Dyachenko M, Glaser G, Travers A, Muskhelishvili G.

Mol Microbiol. 2004 Jul;53(1):143-52.

41.

Sox8 is a specific marker for muscle satellite cells and inhibits myogenesis.

Schmidt K, Glaser G, Wernig A, Wegner M, Rosorius O.

J Biol Chem. 2003 Aug 8;278(32):29769-75. Epub 2003 Jun 2.

42.

Crystal structure of the intrinsically flexible addiction antidote MazE.

Loris R, Marianovsky I, Lah J, Laeremans T, Engelberg-Kulka H, Glaser G, Muyldermans S, Wyns L.

J Biol Chem. 2003 Jul 25;278(30):28252-7. Epub 2003 May 12.

43.
44.

Sox10 is an active nucleocytoplasmic shuttle protein, and shuttling is crucial for Sox10-mediated transactivation.

Rehberg S, Lischka P, Glaser G, Stamminger T, Wegner M, Rosorius O.

Mol Cell Biol. 2002 Aug;22(16):5826-34.

45.

Promoter protection by a transcription factor acting as a local topological homeostat.

Rochman M, Aviv M, Glaser G, Muskhelishvili G.

EMBO Rep. 2002 Apr;3(4):355-60. Epub 2002 Mar 15.

46.

Programmed cell death in Escherichia coli: some antibiotics can trigger mazEF lethality.

Sat B, Hazan R, Fisher T, Khaner H, Glaser G, Engelberg-Kulka H.

J Bacteriol. 2001 Mar;183(6):2041-5.

47.

Regulation of Escherichia coli RelA requires oligomerization of the C-terminal domain.

Gropp M, Strausz Y, Gross M, Glaser G.

J Bacteriol. 2001 Jan;183(2):570-9.

48.

The regulation of the Escherichia coli mazEF promoter involves an unusual alternating palindrome.

Marianovsky I, Aizenman E, Engelberg-Kulka H, Glaser G.

J Biol Chem. 2001 Feb 23;276(8):5975-84. Epub 2000 Nov 8.

49.

Addiction modules and programmed cell death and antideath in bacterial cultures.

Engelberg-Kulka H, Glaser G.

Annu Rev Microbiol. 1999;53:43-70. Review.

PMID:
10547685
50.

rexB of bacteriophage lambda is an anti-cell death gene.

Engelberg-Kulka H, Reches M, Narasimhan S, Schoulaker-Schwarz R, Klemes Y, Aizenman E, Glaser G.

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15481-6.

Supplemental Content

Loading ...
Support Center